Details

Autor(en) / Beteiligte

• Lambiase, Alessandro, MD, PhD
• Sullivan, Benjamin D., PhD
• Schmidt, Tannin A., PhD
• Sullivan, David A., PhD
• Jay, Gregory, MD, PhD
• Truitt, Edward R., JD
• Bruscolini, Alice, MD, PhD
• Sacchetti, Marta, MD, PhD
• Mantelli, Flavio, MD, PhD

Titel

A Two-Week, Randomized, Double-masked Study to Evaluate Safety and Efficacy of Lubricin (150 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients with Moderate Dry Eye Disease

Ist Teil von

• The ocular surface, 2017-01, Vol.15 (1), p.77-87

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Purpose The objective of this clinical trial (NCT02507934) was to assess the efficacy and safety of recombinant human lubricin as compared to a 0.18% sodium hyaluronate (HA) eye drop in subjects with moderate dry eye disease (DED). Methods DEWS Grade 2-3 subjects were randomized to use lubricin (N=19, 51.9±11.8 years) or HA (N=20, 61.8±13.3 years). After a saline washout period, subjects administered BID therapy for 7 days, followed by instillation as needed (2–6 drops per eye) for 7 days. Visual analog scale (VAS) including foreign body sensation, burning/stinging, itching, pain, sticky feeling, blurred vision and photophobia were primary outcomes, with secondary endpoints of corneal fluorescein staining, Schirmer test, tear film breakup time (TFBUT), eyelid and conjunctival erythema and number of instillations compared at day 14. Results The primary endpoint was met. Lubricin supplementation achieved greater than a 72% reduction from baseline in foreign body sensation (p<.013), burning/stinging, pain, sticky feeling (p<.0432), blurred vision (p<.0013), and photophobia (p<.011) in at least one eye. Lubricin also showed significant improvement in fluorescein staining (OD/OS: 43.8%, 50.0%, vs. 26.5%, 23.3%, p<.0398, p<.0232), TFBUT (p<.010), SANDE frequency (p<.0435), eyelid erythema (p<0.004), conjunctival erythema (p<.0013), and instillations (p<0.04) as compared to HA. No treatment-related adverse events occurred during the investigation. Conclusions: Recombinant human lubricin was shown to produce significant improvement in both signs and symptoms of dry eye disease as compared to HA.